Spain's AEMPS recommends stronger contraception when starting Mounjaro if you take the pill: what changes
Spain's medicines agency updated its tirzepatide guidance on November 19: women using oral contraceptives should add a barrier method for four weeks, or switch to a non-oral method.
Photo: Raimond Spekking / Wikimedia Commons · CC BY-SA 4.0
A tirzepatide (Mounjaro) pen. Reference photo: Raimond Spekking / Wikimedia Commons (CC BY-SA 4.0).
The Spanish Agency for Medicines and Health Products (AEMPS) published a safety note on November 19, 2026 with new recommendations for women who use tirzepatide (Mounjaro) and take oral contraceptives.
The reason: the available information on how this drug affects the effectiveness of the pill is limited.
What the AEMPS recommends
If a woman uses Mounjaro and an oral contraceptive, the AEMPS recommends:
- Also using a barrier method (for example, a condom) for the 4 weeks after starting treatment and for the 4 weeks after each dose increase.
- Or, instead, switching to a non-oral contraceptive method.
The recommendation comes from a review by the safety committee (PRAC) and the human medicines committee (CHMP) of the European Medicines Agency, of which the AEMPS is a member.
What was already known
Current warnings say tirzepatide is not recommended during pregnancy or in women of childbearing potential who do not use contraception. Anyone who wants to become pregnant should stop treatment at least one month beforehand, and if pregnancy occurs, treatment should be stopped.
Mounjaro is approved for type 2 diabetes and for weight management in adults with obesity, or with overweight and another health condition.
What comes next
After the European Commission's decision, the marketing authorization holder will send a letter to health professionals, and the recommendations will be added to the product information and leaflet.
The AEMPS is Spain's agency, and its note refers to products authorized there. If you use tirzepatide and an oral contraceptive, do not change or stop anything on your own: talk to your doctor or pharmacist about the best option for you.
Read also: El ISP alerta sobre Ozempic y la pérdida repentina de visión · Un neurólogo advierte sobre algunos antigripales y el riesgo de ictus
Sources
- AEMPS: Actualización de las recomendaciones anticonceptivas durante el tratamiento con tirzepatida (19 nov 2026)
- Fundación redGDPS: La AEMPS actualiza las recomendaciones anticonceptivas durante el tratamiento con tirzepatida
- ConSalud: Sanidad recomienda reforzar la anticoncepción al iniciar Mounjaro si están tomando la píldora
For information only. It does not replace advice from a health professional. Medical disclaimer